New combo therapy aims to tackle tough pancreatic tumors

NCT ID NCT02207465

Ongoing Disease control Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 1 trial tests a combination of radiation therapy and the chemotherapy drug Abraxane (nab-paclitaxel) in people with pancreatic cancer that cannot be surgically removed. The goal is to find the safest and most effective doses to improve local tumor control and survival. The study involves 42 participants and will also explore adding another drug, paricalcitol, in some cases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Abraxane (nab-paclitaxel) combined with radiation therapy
What this could lead to: If successful, this could lead to a more effective treatment option for people with pancreatic cancer that cannot be removed by surgery, potentially improving local tumor control and survival.
What could go wrong: This is an early phase 1 trial with only 42 participants, so results may not apply to everyone. The main goal is to find safe doses, not to prove effectiveness. Side effects from the combination of chemotherapy and radiation are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE PANCREATIC CANCER TREATED WITH CHEMORADIOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE RESECTABLE PANCREATIC CANCER TREATED WITH CHEMORADIOTHERAPY LOCALLY ADVANCED UNRESECTABLE PANCREATIC CANCER TREATED WITH CHEMORADIOTHERAPY

Contacts and locations

Locations

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Chester County Hospital

West Chester, Pennsylvania, 19380, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.